Palisade Bio (NASDAQ:PALI – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report issued on Saturday, Wall Street Zen reports.
A number of other brokerages also recently commented on PALI. Weiss Ratings reissued a “sell (e+)” rating on shares of Palisade Bio in a research note on Monday, October 12th. Oppenheimer restated an “outperform” rating on shares of Palisade Bio in a report on Wednesday, October 21st. HC Wainwright decreased their price target on shares of Palisade Bio to $5.00 and set a “buy” rating for the company in a research report on Wednesday, November 11th. Finally, Raymond James Financial assumed coverage on Palisade Bio in a report on Thursday, October 8th. They issued an “outperform” rating and a $6.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $9.00.
View Our Latest Analysis on PALI
Palisade Bio Stock Performance
Palisade Bio (NASDAQ:PALI – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). Sell-side analysts forecast that Palisade Bio will post -0.24 EPS for the current fiscal year.
Hedge Funds Weigh In On Palisade Bio
Several hedge funds and other institutional investors have recently bought and sold shares of PALI. Legal & General Group Plc purchased a new position in Palisade Bio in the 2nd quarter worth approximately $30,000. CTC Alternative Strategies Ltd. acquired a new stake in Palisade Bio in the first quarter valued at approximately $31,000. GSA Capital Partners LLP acquired a new stake in Palisade Bio in the second quarter valued at approximately $54,000. Two Sigma Securities LLC purchased a new stake in shares of Palisade Bio during the second quarter valued at approximately $57,000. Finally, Susquehanna International Group LLP purchased a new stake in shares of Palisade Bio during the second quarter valued at approximately $65,000. 11.79% of the stock is owned by institutional investors and hedge funds.
Top Palisade Bio Stories
Here are a few of the latest stories about PALI:
- Positive Sentiment: Brookline raised its 2030 EPS forecast to $0.44 from $0.39, suggesting a modestly better long-term outlook, though the company is still forecast to post losses through 2029.
- Negative Sentiment: HC Wainwright reduced its price target for PALI, adding to the cautious analyst outlook. Palisade Bio Stock Gets Price Target Reduction from HC Wainwright
- Negative Sentiment: Wall Street Zen downgraded the stock to “Strong Sell,” a further negative signal for sentiment. Palisade Bio Stock Moved Down to Strong Sell by Wall Street Zen
Palisade Bio Company Profile
Palisade Bio is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions. Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn’s disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery.
Further Reading
- Five stocks we like better than Palisade Bio
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
